COT Share Price

Open 0.46 Change Price %
High 0.49 1 Day 0.02 4.35
Low 0.45 1 Week -0.04 -7.69
Close 0.48 1 Month -0.02 -4.00
Volume 69003 1 Year 0.18 60.00
52 Week High 0.90
52 Week Low 0.21
COT Important Levels
Resistance 2 0.52
Resistance 1 0.50
Pivot 0.47
Support 1 0.46
Support 2 0.44
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
BVQ 0.02 100.00%
CQR 0.02 100.00%
CQR 0.02 100.00%
BOR 0.02 100.00%
BOR 0.02 100.00%
BOR 0.02 100.00%
BOR 0.02 100.00%
WRP 0.02 100.00%
FTI 0.06 100.00%
FTI 0.06 100.00%
More..
CVE Canada Top Losers Stocks
EEV 0.00 -100.00%
MXM 0.00 -100.00%
MXM 0.00 -100.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
More..

Critical Outcome (CVE: COT)

COT Technical Analysis 4
As on 5th Dec 2016 COT Share Price closed @ 0.48 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.52 & Strong Sell for SHORT-TERM with Stoploss of 0.54 we also expect STOCK to react on Following IMPORTANT LEVELS.
COT Target for December
1st Target up-side 0.58
2nd Target up-side 0.65
3rd Target up-side 0.71
1st Target down-side 0.4
2nd Target down-side 0.33
3rd Target down-side 0.27
COT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.criticaloutcome.com
COT Address
COT
700 Collip Circle
Suite 213
London, ON N6G 4X8
Canada
Phone: 519-858-5157
Fax: 519-858-5179
Interactive Technical Analysis Chart Critical Outcome ( COT CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Critical Outcome
COT Business Profile
Critical Outcome Technologies Inc. operates as a biotechnology company in Canada. The company focuses on applying CHEMSAS, a proprietary computer based technology, which identifies, profiles, optimizes, selects, and validates commercially viable drug candidates at the earliest stage of preclinical drug development. It develops drug candidates for the treatment of various cancers, such as small cell lung, acute myelogenous leukemia, ovarian, endometrial, pancreatic, brain, breast, and colon cancers, as well as human immunodeficiency virus, Alzheimer’s disease, and multiple sclerosis. The company’s lead oncology compound consists of COTI-2, a molecule in Phase I clinical trials, which acts by inhibiting protein kinase B phosphorylation that leads to caspase-9 activation in cancer cells resulting in tumor cell death. Critical Outcome Technologies Inc. is based in London, Canada.